

# **Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis**

Yongpeng Xie<sup>1,2&</sup>, Luyao Chen<sup>1&</sup>, Xin Ma<sup>1</sup>, Hongzhao Li<sup>1</sup>, Liangyou Gu<sup>1</sup>, Yu Gao<sup>1</sup>, Yang Fan<sup>1</sup>, Yu Zhang<sup>1</sup>, Xu Zhang<sup>1\*</sup>

& These authors equally dedicated to this article.

<sup>1</sup> State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China

<sup>2</sup> Medical School, Nankai University, Tianjin, People's Republic of China

\* Corresponding author: Xu Zhang, M.D.

Department of Urology, Chinese PLA General Hospital, Beijing 100853, P.R. China.

Tel: +86-10-66938008; Fax: +86-10-68223575

E-mail: xzhang@tjh.tjmu.edu.cn

**Supplemental table 1. Pooled HR (95% CI) of sensitivity analysis for the effect of Ki-67 expression on OS**

<b>Study Omitted</b>	<b>Pooled HR</b>	<b>95% CI</b>	<b>P Value</b>	<b>Model</b>	<b>Heterogeneity <math>I^2</math> (%)</b>	<b>P Value</b>
Pinto (2005)	1.84	1.35-2.51	<0.001	fixed	0	0.895
Kankuri (2006)	2.01	1.46-2.77	<0.001	fixed	0	0.510
Gontero (2008)	1.96	1.43-2.70	<0.001	fixed	0	0.432
Kankuri-Tammilehto (2010)	2.06	1.44-2.94	<0.001	fixed	0	0.479
Virman (2016)	1.86	1.22-2.82	0.004	fixed	0	0.443
Combined	1.95	1.44-2.64	<0.001	fixed	0	0.594

HR: hazard ratio; CI: confidence interval; OS: overall survival.

**Supplemental table 2. Pooled HR (95% CI) of sensitivity analysis for the effect of Ki-67 expression on CSS**

<b>Study Omitted</b>	<b>Pooled HR</b>	<b>95% CI</b>	<b>P Value</b>	<b>Model</b>	<b>Heterogeneity <math>I^2</math> (%)</b>	<b>P Value</b>
Rioux-Leclercq (2000)	1.65	1.45-1.87	<0.001	fixed	0	0.507
Yuba (2001)	1.67	1.47-1.89	<0.001	fixed	12.2	0.331
Cheville (2002)	1.69	1.49-1.92	<0.001	fixed	2.6	0.416
Bui (2004)	1.66	1.46-1.89	<0.001	fixed	11.9	0.333
Kim (2004)	1.69	1.49-1.93	<0.001	fixed	5.7	0.389
Kim (2005)	1.80	1.53-2.11	<0.001	fixed	0	0.509
Tollefson (2007)	1.66	1.45-1.91	<0.001	fixed	12.3	0.330
Parker (2009)	1.62	1.41-1.86	<0.001	fixed	1.7	0.423
Zubac (2009)	1.65	1.45-1.87	<0.001	fixed	1.5	0.425
Weber (2013)	1.65	1.46-1.87	<0.001	fixed	0	0.559
Gayed (2014)	1.66	1.46-1.88	<0.001	fixed	5.2	0.393
Combined	1.67	1.47-1.89	<0.001	fixed	2.7	0.417

HR: hazard ratio; CI: confidence interval; CSS: cancer-specific survival.

**Supplemental table 3. Pooled HR (95% CI) of sensitivity analysis for the effect of Ki-67 expression on DFS**

<b>Study Omitted</b>	<b>Pooled HR</b>	<b>95% CI</b>	<b>P Value</b>	<b>Model</b>	<b>Heterogeneity <math>I^2</math> (%)</b>	<b>P Value</b>
Lehmann (2004)	2.36	1.62-3.43	<0.001	fixed	0	0.884
Dudderidge (2005)	2.78	1.77-4.37	<0.001	fixed	0	0.505
Kankuri (2006)	2.73	1.84-4.06	<0.001	fixed	0	0.539
Gayed (2014)	2.43	1.65-3.57	<0.001	fixed	0	0.549
Teng (2014)	2.56	1.73-3.79	<0.001	fixed	0	0.452
Zheng (2014)	2.63	1.79-3.85	<0.001	fixed	0	0.473
Combined	2.56	1.79-3.68	<0.001	fixed	0	0.598

HR: hazard ratio; CI: confidence interval; DFS: disease-free survival.